Insights from a phase II clinical trial with CL2020 Muse cell-based therapeutic for Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of motor functions, which eventually leads to death within 5 years of its onset. This disease causes weakness and atrophy of limbs and other muscles, which affect mobility speech, eating, and even breathing in patients. Some drugs, including riluzole, edaravone, and sodium phenylbutyrate/taurursodiol are used for treating ALS, but with limited therapeutic benefits. Therefore, novel, effective ALS treatments are the need of the hour.
Multilineage-differentiating stress-enduring (Muse) cells are pluripotent stem cells ...










